Tag: operations

Leuven, Belgium, June 12, 2025 – AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary Launch-iT technology, announced today the appointment of Dieter Weinand as Chair of the Board of Directors, effective June 12, 2025. Mr. Weinand is the former Chief Executive Officer of Bayer Pharma AG with more than 25 years of experience as a senior business leader in the pharmaceutical industry. He takes over from Dr. Jeanne Bolger, who served as Chair since 2022 and will remain on the Board as a non-executive independent director.

BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.

SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP announces that a class action lawsuit has commenced on behalf of investors of Fortrea Holdings Inc. (NASDAQ: FTRE). The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (iii) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; (iv) accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BigBear.ai Holdings, Inc. (NYSE:BBAI) on behalf of long-term stockholders following a class action complaint that was filed against BigBear on April 11, 2025 with a Class Period from March 31, 2022 through March 25, 2025. Our investigation concerns whether the board of directors of BigBear have breached their fiduciary duties to the company.

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against PepGen, Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). Investors have until August 8, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Sheridan, WY, June 11, 2025 (GLOBE NEWSWIRE) -- Breakthrough Nura Wallet technology turns crypto staking from 50-exchange nightmare into simple one-click profit machine

Nura Labs, LLC today filed a game-changing patent that could unlock $180 billion in trapped DeFi value. The Company's breakthrough AI technology transforms impossibly complex crypto staking into automated profit generation through the world's first intelligent wallet.

Patent pending — U.S. Provisional Application No. 63/819,482 protects revolutionary algorithms that automatically optimize staking across hundreds of protocols while users simply hold their crypto in the Nura Wallet.

The $180 Billion Problem Finally Solved

Current crypto staking forces users to become day traders across dozens of platforms simultaneously. This complexity locks out 95% of crypto holders from earning passive income on their assets, leaving massive profits on the table. 

"We just eliminated the biggest barrier in crypto," said the Nura Labs team. "The Nura Wallet embeds institutional-grade AI that acts like a personal hedge fund manager, automatically maximizing yields while users sleep."

Patent-Protected Technology Advantage

The 37-claim patent covers three breakthrough innovations:

● Protocol-Specific AI Models that understand each DeFi protocol's unique mechanics

● Predictive Yield Optimization that forecasts market scenarios for maximum returns

● Autonomous Cross-Protocol Management that seamlessly handles complex multi-chain operations

Explosive Performance Results

Real testing delivers game-changing results:

● 23% higher staking yields vs manual management

● 67% lower transaction costs through intelligent execution

● 89% less time required for portfolio optimization

● 2x better risk-adjusted returns through AI diversification

Massive Market Opportunity

With the DeFi market growing 300% annually and less than 10% user penetration due to complexity, Nura Labs is positioned to capture enormous market share through patent-protected technology that makes institutional-grade staking accessible to everyone.

Multiple Revenue Streams

The patent enables lucrative business opportunities:

● Technology licensing to major crypto platforms

● Direct Nura Wallet operations targeting millions of users

● Strategic partnerships with top DeFi protocols

Aggressive Growth Timeline

Q3 2025: Beta launch and strategic partnerships

Q4 2025: Major protocol integrations

Q1 2026: Public launch capturing mainstream market

Q2 2026: International expansion and institutional features

Investment Catalyst

This patent filing creates a defensible competitive moat around the most valuable innovation in DeFi infrastructure. Nura Labs seeks strategic investors and partners to capitalize on this massive market opportunity. 

"We've built the technology that finally makes crypto work for everyone," continued the team. "This patent protects our path to becoming the dominant wallet in the fastest-growing sector of finance."

Contact Information

Corporate Development: investors@nura.gg

Strategic Partnerships: partnerships@nura.gg

Media Inquiries: media@nura.gg

Nura Labs, LLC

30 N Gould St, STE R, Sheridan, WY 82801

Website: https://nura.gg/

Legal Notice

Patent pending — U.S. Provisional Application No. 63/819,482, filed on 06/06/25. Cryptocurrency investments involve substantial risk. Investment opportunities limited to accredited investors.

Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities.